{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:10:15Z","timestamp":1789665015065,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccination and Treatment Evaluation Unit","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}]},{"name":"Vaccine and Treatment Evaluation Unit","award":["HHSN2722013000201"],"award-info":[{"award-number":["HHSN2722013000201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-024-01465-1","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:04:27Z","timestamp":1734347067000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetics of Meropenem Across the Adult Lifespan"],"prefix":"10.1007","volume":"64","author":[{"given":"Angelique E.","family":"Boutzoukas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Balevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Hemmersbach-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Winokur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M. J.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta K.","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgar.2020.02.022","volume":"22","author":"M Falcone","year":"2020","unstructured":"Falcone M, Paul M, Tiseo G, Yahav D, Prendki V, Friberg LE, et al. Considerations for the optimal management of antibiotic therapy in elderly patients. J Glob Antimicrob Resist. 2020;22:325\u201333.","journal-title":"J Glob Antimicrob Resist."},{"key":"1465_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1465_CR3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","volume":"43","author":"AD Rule","year":"2004","unstructured":"Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated gfr in healthy potential kidney donors. Am J Kidney Dis. 2004;43:112\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1465_CR4","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","volume":"100","author":"AP Herrera","year":"2010","unstructured":"Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: Priorities and opportunities for policy and practice change. Am J Public Health. 2010;100:S105\u201312.","journal-title":"Am J Public Health"},{"key":"1465_CR5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/ageing\/afab003","volume":"50","author":"SN Hilmer","year":"2021","unstructured":"Hilmer SN, Kirkpatrick CMJ. New horizons in the impact of frailty on pharmacokinetics: latest developments. Age Ageing. 2021;50:1054\u201363.","journal-title":"Age Ageing"},{"key":"1465_CR6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/AAC.36.7.1532","volume":"36","author":"BA Christensson","year":"1992","unstructured":"Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36:1532\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"1465_CR7","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/clinids\/24.Supplement_2.S249","volume":"24","author":"YS Moon","year":"1997","unstructured":"Moon YS, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis. 1997;24(Suppl 2):S249\u201355.","journal-title":"Clin Infect Dis"},{"key":"1465_CR8","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1128\/AAC.36.12.2794","volume":"36","author":"A Leroy","year":"1992","unstructured":"Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ici 194,660) and its metabolite (ici 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36:2794\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1465_CR9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0149-2918(04)80001-8","volume":"26","author":"HM Mattoes","year":"2004","unstructured":"Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26:1187\u201398.","journal-title":"Clin Ther"},{"key":"1465_CR10","doi-asserted-by":"crossref","first-page":"e02642","DOI":"10.1128\/AAC.02642-16","volume":"61","author":"PJ Bergen","year":"2017","unstructured":"Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, et al. Substantial impact of altered pharmacokinetics in critically ill patients on the antibacterial effects of meropenem evaluated via the dynamic hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61:e02642-e2716.","journal-title":"Antimicrob Agents Chemother"},{"key":"1465_CR11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","volume":"46","author":"C Li","year":"2006","unstructured":"Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46:1171\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1465_CR12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-016-2172-4","volume":"73","author":"M Usman","year":"2017","unstructured":"Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: Dosing simulations based on renal function. Eur J Clin Pharmacol. 2017;73:333\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"1465_CR13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a pk model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1465_CR14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","volume":"64","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR15","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","volume":"49","author":"WA Krueger","year":"2005","unstructured":"Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1465_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","volume":"54","author":"L Ehmann","year":"2019","unstructured":"Ehmann L, Zoller M, Minichmayr IK, Scharf C, Huisinga W, Zander J, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54:309\u201317.","journal-title":"Int J Antimicrob Agents"},{"key":"1465_CR17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jac\/dkm325","volume":"60","author":"TP Lodise","year":"2007","unstructured":"Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, S\u00f6rgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modelling and monte carlo simulation. J Antimicrob Chemother. 2007;60:1038\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","volume":"44","author":"A Novelli","year":"2005","unstructured":"Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005;44:539\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"1465_CR19","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","volume":"70","author":"A Ramon-Lopez","year":"2015","unstructured":"Ramon-Lopez A, Allen JM, Thomson AH, Dheansa BS, James SE, Hanlon GW, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with monte carlo simulations. J Antimicrob Chemother. 2015;70:882\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jac\/dky434","volume":"74","author":"SAM Dhaese","year":"2019","unstructured":"Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete AG, et al. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother. 2019;74:432\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR21","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/AAC.04166-14","volume":"59","author":"S Jaruratanasirikul","year":"2015","unstructured":"Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, et al. Population pharmacokinetics and monte carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59:2995\u20133001.","journal-title":"Antimicrob Agents Chemother"},{"key":"1465_CR22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.clinthera.2018.07.001","volume":"40","author":"YK Kim","year":"2018","unstructured":"Kim YK, Lee DH, Jeon J, Jang HJ, Kim HK, Jin K, et al. Population pharmacokinetic analysis of meropenem after intravenous infusion in korean patients with acute infections. Clin Ther. 2018;40:1384\u201395.","journal-title":"Clin Ther"},{"key":"1465_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2710.2010.01171.x","volume":"36","author":"T Muro","year":"2011","unstructured":"Muro T, Sasaki T, Hosaka N, Umeda Y, Takemoto S, Yamamoto H, et al. Population pharmacokinetic analysis of meropenem in japanese adult patients. J Clin Pharm Ther. 2011;36:230\u20136.","journal-title":"J Clin Pharm Ther"},{"key":"1465_CR24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/psp4.12319","volume":"7","author":"KM Jamsen","year":"2018","unstructured":"Jamsen KM, Patel K, Nieforth K, Kirkpatrick CMJ. A regression approach to visual predictive checks for population pharmacometric models. CPT Pharmacomet Syst Pharmacol. 2018;7:678\u201386.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1465_CR25","unstructured":"Gastonguay M. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies. In: Annual Meeting of the Population Approach Group Europe. 2011. Athens, Greece."},{"key":"1465_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12248-012-9409-7","volume":"15","author":"J Fang","year":"2013","unstructured":"Fang J, Landersdorfer CB, Cirincione B, Jusko WJ. Study reanalysis using a mechanism-based pharmacokinetic\/pharmacodynamic model of pramlintide in subjects with type 1 diabetes. AAPS J. 2013;15:15\u201329.","journal-title":"AAPS J"},{"key":"1465_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2: e38.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1465_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It\u2019s not just for mice anymore. Clin Infect Dis. 2007;44:79\u201386.","journal-title":"Clin Infect Dis"},{"key":"1465_CR29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouton","year":"2005","unstructured":"Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (pk\/pd) terminology for anti-infective drugs: An update. J Antimicrob Chemother. 2005;55:601\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR30","doi-asserted-by":"crossref","unstructured":"Craig WA (1998) Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1\u201310","DOI":"10.1086\/516284"},{"key":"1465_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of \u201cbug and drug.\u201d Nat Rev Microbiol. 2004;2:289\u2013300.","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl 2","key":"1465_CR32","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Suppl 2):S266\u201375.","journal-title":"Clin Infect Dis"},{"key":"1465_CR33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2017","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. Mic-based dose adjustment: facts and fables. J Antimicrob Chemother. 2017;73:564\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1465_CR34","unstructured":"AstraZeneca Pharmaceuticals LP. Merrem iv (meropenem for injection) [package insert]. U.S. Food and Drug Adminitration website. Last updated: December 2016 [cited 2024 October 1]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf."},{"key":"1465_CR35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","volume":"23","author":"A Denic","year":"2016","unstructured":"Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19\u201328.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1465_CR36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129036","volume":"10","author":"M Baba","year":"2015","unstructured":"Baba M, Shimbo T, Horio M, Ando M, Yasuda Y, Komatsu Y, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS ONE. 2015;10: e0129036.","journal-title":"PLoS ONE"},{"key":"1465_CR37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40620-014-0077-9","volume":"27","author":"E Cohen","year":"2014","unstructured":"Cohen E, Nardi Y, Krause I, Goldberg E, Milo G, Garty M, et al. A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol. 2014;27:635\u201341.","journal-title":"J Nephrol"},{"key":"1465_CR38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI102286","volume":"29","author":"DF Davies","year":"1950","unstructured":"Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496\u2013507.","journal-title":"J Clin Invest"},{"key":"1465_CR39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1681\/ASN.2016020154","volume":"28","author":"A Denic","year":"2017","unstructured":"Denic A, Lieske JC, Chakkera HA, Poggio ED, Alexander MP, Singh P, et al. The substantial loss of nephrons in healthy human kidneys with aging. J Am Soc Nephrol. 2017;28:313\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"1465_CR40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278\u201385.","journal-title":"J Am Geriatr Soc"},{"key":"1465_CR41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000435790","volume":"130","author":"L Malmgren","year":"2015","unstructured":"Malmgren L, McGuigan FE, Berglundh S, Westman K, Christensson A, \u00c5kesson K. Declining estimated glomerular filtration rate and its association with mortality and comorbidity over 10 years in elderly women. Nephron. 2015;130:245\u201355.","journal-title":"Nephron"},{"key":"1465_CR42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/geronj\/31.2.155","volume":"31","author":"JW Rowe","year":"1976","unstructured":"Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155\u201363.","journal-title":"J Gerontol"},{"key":"1465_CR43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752\u201362.","journal-title":"Lancet"},{"key":"1465_CR44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2125.2010.03825.x","volume":"71","author":"SN Hilmer","year":"2011","unstructured":"Hilmer SN, Tran K, Rubie P, Wright J, Gnjidic D, Mitchell SJ, et al. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011;71:224\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"1465_CR45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-014-1652-7","volume":"70","author":"C Johnston","year":"2014","unstructured":"Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70:549\u201355.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01465-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:48:08Z","timestamp":1738237688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01465-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01465-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"24 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US Department of Health and Human Services, through contract no. HHSN272201500002C (The EMMES Company) and a Vaccine and Treatment Evaluation Units award under contract no. HHSN272201300017I (Duke University) and contract no. HHSN2722013000201 (University of Iowa). KES also received support from the National Institute on Aging, Duke Pepper Older Americans Independence Center, NIA P30AG028716. MCW receives support for research from the NIH [1U24-MD016258], NIAID [HHSN272201500006I, HHSN272201300017I, 1K24-AI143971], Eunice Kennedy Shriver National Institute of Child Health and Human Development [HHSN275201000003I], US FDA [5U18-FD006298], and industry for drug development in adults and children. This work was also supported by the NIAID of the NIH (grant number 5T32AI100851 to MHM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AEB receives support from the NIH, the Thrasher Research Foundation, the Pediatric Trials Network (HHSN275201800003I), and the Biogen Foundation. SJB receives support from the NIH, the US Food and Drug Administration, the Childhood Arthritis and Rheumatology Research Alliance, Purdue Pharma, and consulting for UCB and Rutgers University. SJB receives support from the NIH, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), consults for UCB, Rutgers University, and CARRA, and serves on an NIH data and safety monitoring board. EBW has received support from Pfizer, Moderna, Sequiris, Najit Technologies, and Clinetic as an investigator for clinical trials or studies and has served as an advisor to Vaxcyte and a consultant to Iliad Biotechnologies. The remaining authors have no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data are to be made available as widely as possible while safeguarding the privacy of patients and protecting confidential and proprietary data. Data can be requested from the study team.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was approved by Duke University Health System institutional review board (IRB) Pro00083161 and University of Iowa IRB and was performed in accordance with the ethical standards set forth in the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A written informed consent document was used that embodied the elements of informed consent as described in the Declaration of Helsinki and adhered to the International Committee for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Harmonized Tripartite Guideline for Good Clinical Practice. Informed consent was obtained in accordance with 21 CFR 50.25 and 45 CFR 46 before any protocol-specified procedures or interventions were carried out. Participants or their legally authorized representatives provided written consent to participate in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients signed informed consent regarding the publishing of their de-identified data. They were informed that their identity will not be revealed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MHM, PLW, CBL, KG, AWC, MCW, TC, GA, CMJK, GKS, EBW, and KES contributed to study conception and design of the analysis. MHM, PLW, CBL, KG, AWC, MCW, TC, GA, CMJK, GKS, EBW, and KES acquired the data. CBL performed the data analysis, including all pharmacometric modeling and simulations, and wrote the pharmacokinetic report. AEB wrote the initial draft of the manuscript; All authors interpreted the data for the work and revised the work critically for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}